Sponsors (2)
The bill creates structural statutory headings that could enable clearer exclusivity rules and future investment in biosimilars, but by leaving substantive details unspecified it risks short-term regulatory uncertainty and the possibility that later changes could restrict competition and raise drug costs.
Biologic product developers may gain more predictable exclusivity rules if Congress fills the new statutory headings, which could encourage investment in biosimilars and interchangeable products.
The Food and Drug Administration and biologic product applicants receive a clearer statutory structure that distinguishes exclusivity for interchangeable biologics versus reference products, aiding regulatory clarity for implementation.
Patients with chronic conditions and hospital health systems could face delayed competition and higher drug prices if subsequent substantive changes narrow exclusivity for biosimilars or interchangeables.
Biologic product applicants and the FDA face short-term regulatory uncertainty because the amendment creates expectations of substantive changes without specifying details or timelines for implementation.
Based on analysis of 2 sections of legislative text.
Reorganizes the biologics exclusivity statute by adding two subheadings separating exclusivity for first interchangeable biological products and for reference products; adds no substantive text.
Amends the federal biologics statute to create two labeled subheadings that separate exclusivity rules into “exclusivity for first interchangeable biological products” and “exclusivity for reference products.” The change is structural only: it inserts headings without adding substantive text, funding, deadlines, or new regulatory requirements, so it has no immediate substantive legal effect but could prepare the statute for later substantive additions or clarifications.
Introduced April 16, 2026 by Margaret Wood Hassan · Last progress April 16, 2026